Health

STAT+: New federal rule will require prescription drug middlemen to share secret payments data

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 29/10/2026, 16:51:24 UTC.

Briefings

The Trump administration finalized a regulation requiring pharmacy benefit managers (PBMs) to disclose all fees and compensation from drugmakers, consulting firms, and brokers to employers. Disclosures must start July 1, 2027, covering drug rebates, spread pricing, and financial relationships that could create conflicts of interest. The rule applies to over 70 PBMs and 130,000 employers, estimated to save more than $800 million annually through lower drug costs.

Key points

• The Trump administration finalized a regulation requiring pharmacy benefit managers (PBMs) to disclose all fees and compensation from drugmakers, consulting firms, and brokers to employers.
• Disclosures must start July 1, 2027, covering drug rebates, spread pricing, and financial relationships that could create conflicts of interest.

Context

This regulation represents a significant shift in pharmaceutical reimbursement transparency, moving from voluntary reporting to mandatory disclosure of complex financial relationships between drug manufacturers, intermediaries, and employers.

Limitations

Data is limited to the specific federal rule details provided; no independent verification of the $800 million savings estimate or the 70 PBMs and 130,000 employers figures is available.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 29/10/2026, 17:23:13 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeievqavz2bimywdp6iuaskqnkbbuqw7mx7csn2674ilcrhowmhm5mi